vs
Side-by-side financial comparison of Magnera Corp (MAGN) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $792.0M, roughly 1.8× Magnera Corp). Organon & Co. runs the higher net margin — 10.0% vs -4.3%, a 14.3% gap on every dollar of revenue. On growth, Magnera Corp posted the faster year-over-year revenue change (12.8% vs -3.5%). Over the past eight quarters, Magnera Corp's revenue compounded faster (54.9% CAGR vs -4.7%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
MAGN vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $1.5B |
| Net Profit | $-34.0M | $146.0M |
| Gross Margin | 12.2% | 53.6% |
| Operating Margin | 1.8% | — |
| Net Margin | -4.3% | 10.0% |
| Revenue YoY | 12.8% | -3.5% |
| Net Profit YoY | 43.3% | 67.8% |
| EPS (diluted) | $-0.95 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $792.0M | $1.5B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $839.0M | $1.6B | ||
| Q1 25 | $824.0M | $1.5B | ||
| Q4 24 | $702.0M | $1.6B | ||
| Q3 24 | $332.1M | $1.6B | ||
| Q2 24 | $556.0M | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $-34.0M | $-205.0M | ||
| Q3 25 | — | $160.0M | ||
| Q2 25 | $-18.0M | $145.0M | ||
| Q1 25 | $-41.0M | $87.0M | ||
| Q4 24 | $-60.0M | $109.0M | ||
| Q3 24 | $-15.2M | $359.0M | ||
| Q2 24 | $19.0M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | 12.2% | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | 10.7% | 54.8% | ||
| Q1 25 | 10.7% | 55.6% | ||
| Q4 24 | 10.1% | 56.3% | ||
| Q3 24 | 10.7% | 58.3% | ||
| Q2 24 | 6.6% | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | -9.8% | ||
| Q3 25 | — | 15.2% | ||
| Q2 25 | 1.5% | 14.4% | ||
| Q1 25 | 0.5% | 6.7% | ||
| Q4 24 | -3.1% | 8.1% | ||
| Q3 24 | 0.9% | 13.1% | ||
| Q2 24 | 3.1% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | -4.3% | -13.6% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | -2.1% | 9.1% | ||
| Q1 25 | -5.0% | 5.8% | ||
| Q4 24 | -8.5% | 6.8% | ||
| Q3 24 | -4.6% | 22.7% | ||
| Q2 24 | 3.4% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $-0.95 | $-0.78 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | $-0.51 | $0.56 | ||
| Q1 25 | $-1.15 | $0.33 | ||
| Q4 24 | $-1.69 | $0.42 | ||
| Q3 24 | $-0.33 | $1.38 | ||
| Q2 24 | $0.60 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.0M | — |
| Total DebtLower is stronger | $1.9B | — |
| Stockholders' EquityBook value | $1.0B | — |
| Total Assets | $3.9B | — |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $264.0M | $574.0M | ||
| Q3 25 | — | $672.0M | ||
| Q2 25 | $276.0M | $599.0M | ||
| Q1 25 | $282.0M | $547.0M | ||
| Q4 24 | $215.0M | $675.0M | ||
| Q3 24 | $230.0M | $763.0M | ||
| Q2 24 | $33.9M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.9B | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | $2.0B | $8.9B | ||
| Q1 25 | $2.0B | $9.0B | ||
| Q4 24 | $2.0B | $8.9B | ||
| Q3 24 | $2.0B | $8.7B | ||
| Q2 24 | $877.4M | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $752.0M | ||
| Q3 25 | — | $906.0M | ||
| Q2 25 | $1.1B | $733.0M | ||
| Q1 25 | $1.1B | $542.0M | ||
| Q4 24 | $1.1B | $472.0M | ||
| Q3 24 | $2.1B | $493.0M | ||
| Q2 24 | $2.4B | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $12.9B | ||
| Q3 25 | — | $13.6B | ||
| Q2 25 | $4.1B | $13.5B | ||
| Q1 25 | $4.1B | $13.2B | ||
| Q4 24 | $4.0B | $13.1B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $1.5B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.86× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | 1.77× | 12.14× | ||
| Q1 25 | 1.83× | 16.52× | ||
| Q4 24 | 1.80× | 18.81× | ||
| Q3 24 | 0.91× | 17.75× | ||
| Q2 24 | 0.37× | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | — |
| Free Cash FlowOCF − Capex | $-13.0M | — |
| FCF MarginFCF / Revenue | -1.6% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.0M | $141.0M | ||
| Q3 25 | — | $264.0M | ||
| Q2 25 | $0 | $220.0M | ||
| Q1 25 | $65.0M | $75.0M | ||
| Q4 24 | $-58.0M | $390.0M | ||
| Q3 24 | $12.2M | $141.0M | ||
| Q2 24 | $38.0M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-13.0M | $96.0M | ||
| Q3 25 | — | $218.0M | ||
| Q2 25 | — | $181.0M | ||
| Q1 25 | $42.0M | $43.0M | ||
| Q4 24 | $-74.0M | $335.0M | ||
| Q3 24 | $3.6M | $99.0M | ||
| Q2 24 | $23.0M | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | -1.6% | 6.4% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | 5.1% | 2.8% | ||
| Q4 24 | -10.5% | 21.0% | ||
| Q3 24 | 1.1% | 6.3% | ||
| Q2 24 | 4.1% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 3.0% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 1.5% | 2.4% | ||
| Q1 25 | 2.8% | 2.1% | ||
| Q4 24 | 2.3% | 3.5% | ||
| Q3 24 | 2.6% | 2.7% | ||
| Q2 24 | 2.7% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | 2.00× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
